• About
  • HS
  • ELN28
  • Team
  • Talk To Us
  • News
  • Publications

In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development

by ElasmoAdm1n | Jan 6, 2026 | Publications

Obinna C. Ubah, Andrew J. Porter, and Caroline J. Barelle Journal of Immunology Research 2020; doi: 10.1155/2020/7283239 Read now…

Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain

by ElasmoAdm1n | Dec 17, 2025 | Publications

Müller MR, Saunders K, Grace C, Jin M, Piche-Nicholas N, Steven J, O’Dwyer R, Wu L, Khetemenee L, Vugmeyster Y, Hickling TP, Tchistiakova L, Olland S, Gill D, Jensen A, Barelle CJ. MAbs. 2012 Nov-Dec; 4(6):673-85. doi: 10.4161/mabs.22242. Read...

Generation and isolation of target-specific single-domain antibodies from shark immune repertoires

by ElasmoAdm1n | Dec 17, 2025 | Publications

Müller MR, O’Dwyer R, Kovaleva M, Rudkin F, Dooley H, Barelle CJ. Methods Mol Biol. 2012; 907:177-94. doi: 10.1007/978-1-61779-974-7_9. Read now… (PubMed)

Characterization of the immunoglobulin repertoire of the spiny dogfish (Squalus acanthias).

by ElasmoAdm1n | Dec 17, 2025 | Publications

Smith LE, Crouch K, Cao W, Müller MR, Wu L, Steven J, Lee M, Liang M, Flajnik MF, Shih HH, Barelle CJ, Paulsen J, Gill DS, Dooley H. Dev Comp Immunol. 2012 Apr; 36(4): 665-79. doi: 10.1016/j.dci.2011.10.007. Epub 2011 Oct 20. Read now… (PubMed)

Shark novel antigen receptors–the next generation of biologic therapeutics?

by ElasmoAdm1n | Dec 17, 2025 | Publications

Barelle C, Gill DS, Charlton K. Adv Exp Med Biol. 2009; 655:49-62. doi: 10.1007/978-1-4419-1132-2_6. Read now… (PubMed)
Next Entries »

Recent Posts

  • Elasmogen Ltd is pleased to announce the appointment of Dr Suhail Nurbhai as Chief Medical Officer
  • Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies
  • Elasmogen Researcher receives prestigious £2m fellowship to help establish him as future UK bioscience leader
  • Elasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners
  • Elasmogen announces grants of 2 new VNAR and soloMER patent families

Recent Comments

No comments to show.
  • Follow

TALK TO US

PRIVACY POLICY

Elasmogen Ltd
Liberty Building
Foresterhill Health Campus
Foresterhill Rd
Aberdeen AB25 2ZP

Visit Us

Elasmogen Ltd

Liberty Building
Foresterhill Health Campus
Foresterhill Rd
Aberdeen AB25 2ZP

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
►
Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
None
Powered by